Safety of reduced dose of mycophenolate mofetil combined with tacrolimus in living-donor liver transplantation
Background/AimsThe dose of mycophenolate mofetil (MMF) has been reduced in Asia due to side effects associated with the conventional fixed dose of 2-3 g/day. We aimed to determine the pharmacokinetics of a reduced dose of MMF and to validate its feasibility in combination with tacrolimus in living-d...
Main Authors: | Hyeyoung Kim, Nam-Joon Yi, Juyeun Lee, Joohyun Kim, Mi-Ra Moon, Jaehong Jeong, Jeong-Moo Lee, Tae Suk You, Suk-Won Suh, Min-Su Park, YoungRok Choi, Geun Hong, Hae Won Lee, Kwang-Woong Lee, Kyung-Suk Suh |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Association for the Study of the Liver
2014-09-01
|
Series: | Clinical and Molecular Hepatology |
Subjects: | |
Online Access: | http://e-cmh.org/upload/pdf/cmh-20-291.pdf |
Similar Items
-
Comparison of mid-term clinical outcome in heart transplantation patients using mycophenolate mofetil vs. enteric-coated mycophenolate sodium
by: Kina Jeon, et al.
Published: (2022-08-01) -
Early calcineurin-inhibitor to belatacept conversion in steroid-free kidney transplant recipients
by: Ibrahim Tawhari, et al.
Published: (2022-12-01) -
Mycophenolate mofetil as an alternative treatment for autoimmune hepatitis
by: Seung Woon Park, et al.
Published: (2016-06-01) -
Safety of Tacrolimus Monotherapy within 12 Months after Liver Transplantation in the Era of Reduced Tacrolimus and Mycophenolate Mofetil: National Registry Study
by: Deok Gie Kim, et al.
Published: (2022-05-01) -
Sites of gastrointestinal lesion induced by mycophenolate mofetil: a comparison with enteric-coated mycophenolate sodium in rats
by: Yichen Jia, et al.
Published: (2018-07-01)